Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Posts Earnings Results

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) issued its earnings results on Friday. The company reported ($1.47) earnings per share for the quarter, FiscalAI reports.

Calidi Biotherapeutics Stock Down 5.1%

Shares of CLDI stock traded down $0.03 during trading on Friday, hitting $0.62. 27,622 shares of the company were exchanged, compared to its average volume of 193,971. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.68 and a current ratio of 1.68. The firm has a market capitalization of $1.65 million, a price-to-earnings ratio of -0.01 and a beta of 1.37. The business’s 50-day simple moving average is $0.96 and its 200 day simple moving average is $3.86. Calidi Biotherapeutics has a twelve month low of $0.62 and a twelve month high of $24.80.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company developing cell-based therapies designed to improve the treatment of cancer. The company’s approach uses allogeneic, or donor-derived, stem cells as delivery and support systems for therapeutic agents, with the goal of protecting and enhancing the activity of immune and other anti-cancer cells within tumors. Calidi’s technology platforms include its SuperNova and NeuroNova programs. These platforms are intended to support the development of “off-the-shelf” cell therapies for solid tumors and other difficult-to-treat cancers.